TriangleNCT02082977 · OUTCOME
Part 1: Apparent Terminal Phase Half-life (T1/2) Following Single and Repeat Dose Administration of GSK2816126
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Hours
- Interval / dispersion
- Full Range
- Time frame
- Pre-dose, 0.5, 1, 2, (12, 18 on Day 1 only), 24, and 96 hours post-dose from start of infusion; 0.5, 1, 2, 4, 6 hours from end of infusion on Cycle 1 of Day 1 and Day 15 (Each cycle was of 28 days)
What was measured
Blood samples were collected from participants for pharmacokinetic analysis including T1/2 following single (Day 1) and repeat dose (Day 15) administration of GSK2816126. Pharmacokinetic analysis of GSK2816126 in Part 1 was conducted by non-compartmental methods. Pharmacokinetic parameter derivation for some participants did not strictly conform to the prescribed acceptance criteria and hence data was not available for those participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Analysis population: Pharmacokinetic Population
Groups in this outcome
Part 1:GSK2816126 50 mg Twice-weekly
Eligible participants received GSK2816126 with a starting dose of 50 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 100 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 200 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 400 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 800 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 1200 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 1800 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 2400 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
Part 1:GSK2816126 3000 mg Twice-weekly
Eligible participants received GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
| Group | Source count |
|---|---|
| Part 1:GSK2816126 50 mg Twice-weekly | 2 |
| Part 1:GSK2816126 100 mg Twice-weekly | 1 |
| Part 1:GSK2816126 200 mg Twice-weekly | 1 |
| Part 1:GSK2816126 400 mg Twice-weekly | 1 |
| Part 1:GSK2816126 800 mg Twice-weekly | 3 |
| Part 1:GSK2816126 1200 mg Twice-weekly | 4 |
| Part 1:GSK2816126 1800 mg Twice-weekly | 10 |
| Part 1:GSK2816126 2400 mg Twice-weekly | 12 |
| Part 1:GSK2816126 3000 mg Twice-weekly | 7 |
Reported measurements
Day 1; n=2,0,0,1,3,1,10,10,7
| Group | Source count |
|---|---|
| Part 1:GSK2816126 50 mg Twice-weekly | 2 |
| Part 1:GSK2816126 100 mg Twice-weekly | 0 |
| Part 1:GSK2816126 200 mg Twice-weekly | 0 |
| Part 1:GSK2816126 400 mg Twice-weekly | 1 |
| Part 1:GSK2816126 800 mg Twice-weekly | 3 |
| Part 1:GSK2816126 1200 mg Twice-weekly | 1 |
| Part 1:GSK2816126 1800 mg Twice-weekly | 10 |
| Part 1:GSK2816126 2400 mg Twice-weekly | 10 |
| Part 1:GSK2816126 3000 mg Twice-weekly | 7 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1:GSK2816126 50 mg Twice-weekly | 8.90 | Not reported | 4.3 | 13.5 | Not reported |
| Part 1:GSK2816126 400 mg Twice-weekly | 49.10 | Not reported | 49.1 | 49.1 | Not reported |
| Part 1:GSK2816126 800 mg Twice-weekly | 27.20 | Not reported | 19.4 | 35.2 | Not reported |
| Part 1:GSK2816126 1200 mg Twice-weekly | 14.10 | Not reported | 14.1 | 14.1 | Not reported |
| Part 1:GSK2816126 1800 mg Twice-weekly | 32.55 | Not reported | 23.0 | 39.0 | Not reported |
| Part 1:GSK2816126 2400 mg Twice-weekly | 32.10 | Not reported | 25.6 | 48.8 | Not reported |
| Part 1:GSK2816126 3000 mg Twice-weekly | 21.80 | Not reported | 8.5 | 45.3 | Not reported |
Day 15; n=1,1,0,1,2,4,9,11,4
| Group | Source count |
|---|---|
| Part 1:GSK2816126 50 mg Twice-weekly | 1 |
| Part 1:GSK2816126 100 mg Twice-weekly | 1 |
| Part 1:GSK2816126 200 mg Twice-weekly | 0 |
| Part 1:GSK2816126 400 mg Twice-weekly | 1 |
| Part 1:GSK2816126 800 mg Twice-weekly | 2 |
| Part 1:GSK2816126 1200 mg Twice-weekly | 4 |
| Part 1:GSK2816126 1800 mg Twice-weekly | 9 |
| Part 1:GSK2816126 2400 mg Twice-weekly | 11 |
| Part 1:GSK2816126 3000 mg Twice-weekly | 4 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1:GSK2816126 50 mg Twice-weekly | 46.50 | Not reported | 46.5 | 46.5 | Not reported |
| Part 1:GSK2816126 100 mg Twice-weekly | 36.80 | Not reported | 36.8 | 36.8 | Not reported |
| Part 1:GSK2816126 400 mg Twice-weekly | 39.70 | Not reported | 39.7 | 39.7 | Not reported |
| Part 1:GSK2816126 800 mg Twice-weekly | 27.40 | Not reported | 25.7 | 29.1 | Not reported |
| Part 1:GSK2816126 1200 mg Twice-weekly | 26.85 | Not reported | 23.0 | 33.8 | Not reported |
| Part 1:GSK2816126 1800 mg Twice-weekly | 30.00 | Not reported | 12.2 | 65.7 | Not reported |
| Part 1:GSK2816126 2400 mg Twice-weekly | 25.70 | Not reported | 8.2 | 38.3 | Not reported |
| Part 1:GSK2816126 3000 mg Twice-weekly | 30.20 | Not reported | 15.1 | 40.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.3
- upper Limit
- 13.5
- value
- 8.90
- group Id
- OG003
- lower Limit
- 49.1
- upper Limit
- 49.1
- value
- 49.10
- group Id
- OG004
- lower Limit
- 19.4
- upper Limit
- 35.2
- value
- 27.20
- group Id
- OG005
- lower Limit
- 14.1
- upper Limit
- 14.1
- value
- 14.10
- group Id
- OG006
- lower Limit
- 23.0
- upper Limit
- 39.0
- value
- 32.55
- group Id
- OG007
- lower Limit
- 25.6
- upper Limit
- 48.8
- value
- 32.10
- group Id
- OG008
- lower Limit
- 8.5
- upper Limit
- 45.3
- value
- 21.80
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 10
- group Id
- OG008
- value
- 7
- units
- Participants
- title
- Day 1; n=2,0,0,1,3,1,10,10,7
- categories
- measurements
- group Id
- OG000
- lower Limit
- 46.5
- upper Limit
- 46.5
- value
- 46.50
- group Id
- OG001
- lower Limit
- 36.8
- upper Limit
- 36.8
- value
- 36.80
- group Id
- OG003
- lower Limit
- 39.7
- upper Limit
- 39.7
- value
- 39.70
- group Id
- OG004
- lower Limit
- 25.7
- upper Limit
- 29.1
- value
- 27.40
- group Id
- OG005
- lower Limit
- 23.0
- upper Limit
- 33.8
- value
- 26.85
- group Id
- OG006
- lower Limit
- 12.2
- upper Limit
- 65.7
- value
- 30.00
- group Id
- OG007
- lower Limit
- 8.2
- upper Limit
- 38.3
- value
- 25.70
- group Id
- OG008
- lower Limit
- 15.1
- upper Limit
- 40.3
- value
- 30.20
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 9
- group Id
- OG007
- value
- 11
- group Id
- OG008
- value
- 4
- units
- Participants
- title
- Day 15; n=1,1,0,1,2,4,9,11,4
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 12
- group Id
- OG008
- value
- 7
- units
- Participants
- description
- Blood samples were collected from participants for pharmacokinetic analysis including T1/2 following single (Day 1) and repeat dose (Day 15) administration of GSK2816126. Pharmacokinetic analysis of GSK2816126 in Part 1 was conducted by non-compartmental methods. Pharmacokinetic parameter derivation for some participants did not strictly conform to the prescribed acceptance criteria and hence data was not available for those participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
- dispersion Type
- Full Range
- groups
- description
- Eligible participants received GSK2816126 with a starting dose of 50 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG000
- title
- Part 1:GSK2816126 50 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG001
- title
- Part 1:GSK2816126 100 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG002
- title
- Part 1:GSK2816126 200 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG003
- title
- Part 1:GSK2816126 400 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG004
- title
- Part 1:GSK2816126 800 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG005
- title
- Part 1:GSK2816126 1200 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG006
- title
- Part 1:GSK2816126 1800 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG007
- title
- Part 1:GSK2816126 2400 mg Twice-weekly
- description
- Eligible participants received GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
- id
- OG008
- title
- Part 1:GSK2816126 3000 mg Twice-weekly
- param Type
- MEDIAN
- population Description
- Pharmacokinetic Population
- reporting Status
- POSTED
- time Frame
- Pre-dose, 0.5, 1, 2, (12, 18 on Day 1 only), 24, and 96 hours post-dose from start of infusion; 0.5, 1, 2, 4, 6 hours from end of infusion on Cycle 1 of Day 1 and Day 15 (Each cycle was of 28 days)
- title
- Part 1: Apparent Terminal Phase Half-life (T1/2) Following Single and Repeat Dose Administration of GSK2816126
- type
- SECONDARY
- unit Of Measure
- Hours
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice